investors

Press Releases

DateTitle and SummaryView
June 29, 2017
LOS ANGELES , June 29, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced it has received notification from the NYSE MKT LLC that the Company is not in compliance with certain NYSE MKT continued listing standards relating to stockholders'
ImmunoCellular Therapeutics Receives Notice from NYSE MKT for Noncompliance with Continued Listing Standards
June 21, 2017
LOS ANGELES , June 21, 2017 /PRNewswire/ --- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today provided an update on the strategic review of its financing and development strategies for ICT-107, its patient-specific, dendritic cell-based immunotherapy for patients with
ImmunoCellular Therapeutics Provides Update on Strategic Review and Decision to Suspend Further Patient Randomization for ICT-107 Phase 3 Trial
June 12, 2017
LOS ANGELES , June 12, 2017 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that Anthony J. Gringeri , PhD, President and Chief Executive Officer of ImmunoCellular , will present a corporate overview and business update at the Marcum MicroCap
ImmunoCellular Therapeutics to Present at Marcum MicroCap Conference on June 15, 2017
June 5, 2017
ICT-121 Survival Data Encouraging
ImmunoCellular Therapeutics Announces Data from ICT-121 Phase 1 Trial in Recurrent Glioblastoma at ASCO 2017
May 15, 2017
-Company Considering Potential Strategic Alternatives for ICT-107-
ImmunoCellular Therapeutics Announces First Quarter 2017 Financial Results
March 23, 2017
LOS ANGELES and HOUSTON , March 23, 2017 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) and Memgen, LLC ("Memgen") announce the signing of a non-binding letter of intent to exclusively negotiate the terms  to possibly establish an immuno-oncology strategic
ImmunoCellular Therapeutics and Memgen Announce Letter of Intent for Potential Joint Immuno-Oncology Collaboration
March 14, 2017
LOS ANGELES , March 14, 2017 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2016 filed with the Securities and Exchange Commission on March 9,
ImmunoCellular Therapeutics Receives Audit Opinion With Going Concern Explanation
March 9, 2017
LOS ANGELES , March 9, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced financial results for the fourth quarter and full year 2016 and provided a corporate update.  Anthony Gringeri , PhD, ImmunoCellular's President and Chief Executive
ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
March 6, 2017
LOS ANGELES , March 6, 2017 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that it plans to report fourth quarter and full year 2016 financial results on Thursday, March 9, 2017 . The Company also plans to hold a conference call and webcast
ImmunoCellular Therapeutics to Report Fourth Quarter and Full Year 2016 Financial Results on March 9, 2017
March 6, 2017
- ICT-107 Protocol Amendment Being Implemented in US Clinical Sites; Amended Protocol Submissions Underway in Europe and Canada.
- Successful Sequencing of Target T Cell Receptor Gene is Key Step in Advancing toward Identification of Potential Clinical Candidate in Stem-to-T-Cell Program.
ImmunoCellular Therapeutics Provides Update on ICT-107 Phase 3 Glioblastoma Trial and Announces Advances in Stem-to-T-Cell Research Program
Copyright 2018 by Immunocellular Therapeutics, Ltd.
All Rights Reserved